Inhibition of Kirsten-ras expression in human colorectal cancer using rationally selected Kirsten-ras antisense oligonucleotides

Molecular Cancer Therapeutics

Volumn 1, Issue 1, 2001, Pages 29-41

  Ross, Paul J ^a,b   George, Mark ^a,b   Cunningham, David ^b   DiStefano, Francesca ^a   Andreyev, H Jervoise N ^a,b   Workman, Paul ^a   Clarke, Paul A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AKT1 PROTEIN, HUMAN; ANGIOGENIC FACTOR; ANTISENSE OLIGONUCLEOTIDE; CYCLIN D1; KRAS2 PROTEIN, HUMAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ONCOPROTEIN; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

ADENOCARCINOMA; ARTICLE; CELL CULTURE; COLORECTAL TUMOR; COMPARATIVE STUDY; DNA MICROARRAY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; POINT MUTATION; WESTERN BLOTTING;

ADENOCARCINOMA; ANGIOGENESIS INDUCING AGENTS; BLOTTING, WESTERN; COLORECTAL NEOPLASMS; CYCLIN D1; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHORYLATION; POINT MUTATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0035522657     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Hanahan, D., and Weinberg, R. The hallmarks of cancer. Cell, 100: 57-70, 2000. (Pubitemid 30046295)
2. Garrett, M., and Workman, P. Discovery of new chemotherapeutic drugs for the third millennium. Eur. J. Cancer., 35: 2010-2030, 1999. (Pubitemid 30026222)
3. Barbacid, M. ras genes. Ann. Rev. Biochem., 56: 779-827, 1987.
4. Boguski, M., and McCormick, F. Proteins regulating Ras and its relatives, Nature (Lond.), 366: 643-654, 1993. (Pubitemid 24036012)
5. Campbell, S., Khosravi-Far, R., Rossman, K., Clark, G., and Der, C. Increasing complexity of Ras signaling. Oncogene, 17: 1395-1413, 1998. (Pubitemid 28458409)
6. Shields, J., Pruitt, K., McFall, A., Shaub, A., and Der, C. Understanding Ras: "It ain't over 'til it's over." Trends Cell Biol., 10: 147-154, 2000. (Pubitemid 30171309)
7. Bos, J. L. Ras oncogenes in human cancer: a review [published erratum appears in Cancer Res., 50: 1352, 1990]. Cancer Res., 49: 4682-4689, 1989. (Pubitemid 19213607)
8. Andreyev, H. J., Norman, A. R., Cunningham, D., Oates, J. R., and Clarke, P. A. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst. (Bethesda), 90: 675-684, 1998. (Pubitemid 28222141)
9. Johnson, L., Greenbaum, D., Cichowski, K., Mercer, K., Murphy, E., Schmitt, E., Bronson, R., Umanoff, H., Edelmann, W., Kucherlapati, R., and Jacks, T. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev., 11: 2468-2481, 1997. (Pubitemid 27438829)
10. Umanoff, H., Edelman, W., Pellicer, A., and Kucherlapati, R. The murine N-ras gene is not essential for growth and development. Proc. Natl. Acad. Sci. USA, 92: 1709-1713, 1995.
11. Jones, M. K., and Jackson, J. H. Ras-GRF activates Ha-Ras, but not N-Ras or K-Ras 4B, protein in vivo. J. Biol. Chem., 273: 1782-1787, 1998. (Pubitemid 28133711)
12. Yan, J., Roy, S., Apolloni, A., Lane, A., and Hancock, J. F. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J. Biol. Chem., 273: 24052-24056, 1998. (Pubitemid 28435747)
13. Hamilton, M., and Wolfman, A. Ha-ras and N-ras regulate MAPK activity by distinct mechanisms in vivo. Oncogene, 16: 1417-1428, 1998. (Pubitemid 28151849)
14. Voice, J., Klemke, R., Le, A., and Jackson, J. Four human ras homologues in their ability to activate raf-1, induce transformation and stimulate cell motility. J. Biol. Chem., 274: 17164-17170, 1999.
15. Zuber, J., Tcheritsa, O., Hinzmann, B., Schmitz, A., Grips, M., Hellriegel, Sers, C., Rosenthal, A., and Schafer, R. A genome-wide survey of RAS transformation targets. Nat. Genet., 24: 144-152, 2000.
16. Chen, G., Oh, S., Monia, B. P., and Stacey, D. W. Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J. Biol. Chem., 271: 28259-28265, 1996. (Pubitemid 26374638)
17. Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A. M., and Bos, J. L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med., 319: 525-532, 1988.
18. Andreyev, H., Norman, A., Oates, J., and Cunningham, D, on behalf of The Kirsten ras in-Colorectal-Cancer Collaborative Group. Kirsten ras mutations in patients with colorectal cancer: the "RASCAL II" study. Br. J. Cancer, 85: 692-696, 2001.
19. Hoshino, R., Chatani, Y., Yamori, T., Tsuruo, T., Oka, H., Yoshida, O., S, Ari-i, S, Wada, H., Fujimoto, J., and Kohno, M. Constitutive activation of the 41-/43-kDa mitogen-activated kinase signaling pathway in human tumors. Oncogene, 18: 813-822, 1999. (Pubitemid 29080340)
20. Fry, D., Milam, L., Dillberger, J., Maher, V., and McCormick, J. Malignant transformation of an infinite life span human fibroblast cell strain by transfection with v-Ki-ras. Oncogene, 5: 1415-1418, 1990.
21. Wei, S., and Sedivy, J. M. Expression of catalytically active telomerase does not prevent premature senescence caused by overexpression of oncogenic Ha-Ras in normal human fibroblasts. Cancer Res., 59: 1539-1543, 1999. (Pubitemid 29160123)
22. Giannini, C., Roth, K., Piiper, A., and Zeuzem, S. Enzymatic and antisense effects of a specific anti-Ki-rasribozyme in vitro and in cell culture. Nucleic Acids Res., 27: 2737-2744, 1999. (Pubitemid 29306572)
23. Shirasawa, S., Furuse, M., Yokoyama, N., and Sasazuki, T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science (Wash. DC), 260: 85-88, 1993. (Pubitemid 23122749)
24. Plattner, R., Anderson, M., Sato, K., Fasching, C., Der, C., and Stanbridge, E. Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. Proc. Natl. Acad. Sci. USA, 93: 6665-6670, 1996. (Pubitemid 26230366)
25. Tokunaga, T., Tsuchida, T., Kijima, H., Okamoto, K., Oshika, Y., Sawa, N., Ohnishi, Y., Yamazaki, H., Miura, S., Ueyama, Y., and Nakamura, M. Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line. Br. J. Cancer, 83: 833-839, 2000.
26. Mukhopadhyay, T., Tainsky, M., Cavender, A., and Roth, J. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res., 51: 1744-1748, 1991.
27. Aoki, K., Yoshida, T., Matsumoto, N., Ide, H., Sugimura, T., and Terada, M. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Mol. Carcinog., 20: 251-258, 1997. (Pubitemid 27508889)
28. Aoki, K., Yoshida, T., Sugimura, T., and Terada, M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res., 55: 3810-3816, 1995.
29. Rowinsky, E., Windle, J., and Von Hoff, D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol., 17: 3631-3652, 1999. (Pubitemid 29517936)
30. Sebti, S. M., and Hamilton, A. D. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol. Ther., 74: 103-114, 1997. (Pubitemid 27337356)
31. Prendergast, G. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr. Opin. Cell Biol., 12: 166-173, 2000. (Pubitemid 30142562)
32. Crooke, S. Progress in antisense technology: the end of the beginning. Methods Enzymol., 313: 3-45, 1999.
33. Orr, R., and Monia, B. Antisense therapy for cancer. Curr. Res. Mol. Ther., 1: 102-108, 1998.
34. Giles, R. Antisense oligonucleotide technology: from EST to therapeutics. Curr. Opin. Mol. Ther., 2: 238-252, 2000. (Pubitemid 30435993)
35. Sakakura, C., Hagiwara, A., Tsujimoto, H., Ozaki, K., Sakakibara, T., Oyama, T., Ogaki, M., Imanishi, T., Yamazaki, J., and Takahashi, T. Inhibition of colon cancer cell proliferation by antisense oligonucleotides targeting the messenger RNA of the Ki-ras gene. Anticancer Drugs, 6: 553-561, 1995.
36. Carter, G., Gilbert, C., and Lemoine, N. Effects of antisense oligonucleotides targeting K-ras expression in pancreatic cell lines. Int. J. Oncol., 6: 1105-1112, 1995.
37. Kita, K-I., Saito, S., Morioka, C., and Watanabe, A. Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. Int. J. Cancer, 80: 553-558, 1999. (Pubitemid 29047520)
38. Kawada, M., Yamagoe, S., Murakami, Y., Suzuki, K., Mizuno, S., and Uehara, Y. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene, 15: 629-637, 1997. (Pubitemid 27389926)
39. Andreyev, H., Ross, P., Cunningham, D., and Clarke, P. Antisense treatment directed against Ki-ras mutations in human colorectal adenocarcinoma. Gut, 48: 230-237, 2001. (Pubitemid 32141849)
40. Sohail, M., and Southern, E. Hybridisation of antisense reagents to RNA. Curr. Opin. Mol. Ther., 2: 264-271, 2000.
41. Clarke, P. Labelling and purification of RNA synthesised by in vitro transcription. Methods Mol. Biol., 118: 1-10, 2001.
42. Clarke, P. Analysis of RNA-protein interactions by RNA footprinting and modification interference analysis. Methods Mol. Biol., 118: 73-91, 1995.
43. Mathews, D., Sabina, J., Zuker, M., and Turner, D. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J. Mol. Biol., 288: 911-940, 1999. (Pubitemid 29248642)
44. Clarke, P., Hostein, I., Banerji, U., Di Stefano, F., Maloney, A., Walton, M., Judson, I., and Workman, P. Gene expression profiling of human colon adenocarcinoma cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene, 19: 4125-4133, 2000.
45. Pells, S., Divjak, M., Rimanowski, P., Impey, H., Hawkins, N., Clarke, A., Hooper, M., and Williamson, D. Developmentally-regulated expression of murine K-ras isoforms. Oncogene, 15: 1781-1786, 1997. (Pubitemid 27478620)
46. Chan, S., Wong, S., and Yeung, D. Transcription induction of c-Ki-ras with tumour promoter 12-O-tetradecanoyl phorbol-13-acetate (TPA) in normal and transformed liver cells. Mol. Cell. Biochem., 117: 71-79, 1992.
47. Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., and Pestell, R. G. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem., 270: 23589-23597, 1995.
48. Okada, F., Rak, J. W., Croix, B. S., Lieubeau, B., Kaya, M., Roncari, L., Shirasawa, S., Sasazuki, T., and Kerbel, R. S. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. USA, 95: 3609-3614, 1998.
49. Sohail, M., and Southern, E. Selecting optimal antisense reagents. Adv. Drug Delivery Rev., 44: 23-34, 2000.
50. Lima, W. F., Brown Driver, V., Fox, M., Hanecak, R., and Bruice, T. W. Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J. Biol. Chem., 272: 626-638, 1997. (Pubitemid 27021203)
51. Sohail, M., Akhtar, S., and Southern, E. The folding of large RNAs studied by hybridisation to arrays of complementary oligonucleotides. RNA (NY), 5: 646-655, 1999. (Pubitemid 29218455)
52. Schramm, K., Krause, K., Bittroff-Leben, A., Goldin-Lang, P., Thiel, E., and Kreuser, E. Activated K-ras is involved in regulation of integrin expression in human colon carcinoma cells. Int. J. Cancer, 87: 155-164, 2000. (Pubitemid 30434339)
53. Muise-Helmericks, R., Grimes, H., Bellacosa, A., Malstrom, S., Tsichlis, P., and Rosen, N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J. Biol. Chem., 273: 29864-29872, 1998. (Pubitemid 28510001)
54. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., and Kerbel, R. S. Mutant ras oncogenes up-regulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res., 55: 4575-4580, 1995.
55. Marselos, M., and Michalopoulos, G. Changes in the pattern of aldehyde dehyrogenase activity in primary and metastatic adenocarcinomas of the human colon. Cancer Lett., 34: 27-37, 1987. (Pubitemid 17221566)
56. Lindahl, R. Aldehyde dehydrogenases and their role in carcinogenesis. Crit. Rev. Biochem. Mol. Biol., 27: 283-335, 1992.
57. Nur-E-Kamal, M., Qureshi, M., Ijaz, M., Galadari, S., and Raza, H. Proto-oncogene ras GTPase-linked induction of glutathione-S-transferase by growth factors in PC12 cells. Int. J. Oncol., 16: 1043-1048, 2000.
58. Ban, N., Takahashi, Y., Takayama, T., Kura, T., Katahira, T., Sakamaki, and Niitsu, Y. Transfection of glutathione-S-transferase (GST)-π antisense complementary DNA increases the sensitivity of a colon cancer cell line to Adriamycin, cisplatin, melphalan, and etoposide. Cancer Res., 56: 3577-3582, 1996. (Pubitemid 26251655)
59. Mader, R., Sieder, A., Braun, J., Rizovski, B., Kalipciyan, M., Mueller, M., Jakesz, R., Rainer, H., and Steger, G. Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitro. Biochem. Pharmacol., 54: 1233-1242, 1997. (Pubitemid 27497250)
60. Lehmann, M., Rigot, V., Seidah, N., Marvaldi, J., and Lissitzky, J-C. Lack of integrin α-chain endoproteolytic cleavage in furin-deficient human colon adenocarcinoma cells LoVo. Biochem. J., 317: 803-809, 1996. (Pubitemid 26308254)
61. Yan, Z., Chen, M., Perucho, M., and Friedman, E. Oncogenic Ki-ras but not oncogenic Ha-ras blocks integrin β1-chain maturation in colon epithelial cells. J. Biol. Chem., 272: 30928-30936, 1997. (Pubitemid 27527536)
62. Stallmach, A., Orzechowski, H., Feldmann, P., Riecken, E., Zeitz, M., and Herbst, H. 32/67-kD laminin receptor expression in human colonic neoplasia: elevated transcript levels correlate with the degree of epithelial dysplasia. Am. J. Gastroenterol., 94: 3341-3347, 1999.
63. Feldkamp, M., Lau, N., and Guha, A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene, 18: 7614-7526, 1999.
64. Rak, J., Mitsuhashi, Y., Sheehan, C., Tamir, A., Viloria-Petit, A., Filmus, J., Mansour, S., Ahn, N., and Kerbel, R. Oncogenes and tumour angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res., 60: 490-498, 2000. (Pubitemid 30070780)
65. Ellis, L., and Gallick, G. Promiscuous transcription of vascular endothelial growth factor and survival of tumors. J. Natl. Cancer Inst. (Bethesda), 92: 1030-1031.
66. Vidal, S., Oliveira, M., Kovacs, K., Scheithauer, B., and Lloyd, R. Immunolocalization of vascular endothelial growth factor in the GH3 cell line. Cell Tissue Res., 300: 83-88, 2000. (Pubitemid 30209766)
67. Park, J., Keller, G., and Ferrara, N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell., 4: 1317-1326, 1993. (Pubitemid 24045761)
68. Ozawa, K., Tsukamoto, Y., Hori, O., Kitao, Y., Yanagi, H., Stern, D., and Ogawa, S. Regulation of tumor angiogenesis by oxygen-regulated Protein 150, an inducible endoplasmic reticulum chaperone Cancer Res., 61: 4206-4213, 2001. (Pubitemid 32720990)
69. Ohnami, S., Matsumoto, N., Nakano, M., Aoki, K., Nagasaki, K., Sugimura, T., Terada, M., and Yoshida, T. Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity. Cancer Res., 59: 5565-5571, 1999. (Pubitemid 29526475)
70. Yan, Z., Deng, X., Chen, M., Xu, Y., Ahram, M., Sloane, B. F., and Friedman, E. Oncogenic c-Ki-ras but not oncogenic c-Ha-ras up-regulates CEA expression and disrupts basolateral polarity in colon epithelial cells. J Biol Chem., 272: 27902-27907, 1997. (Pubitemid 27473593)
71. Heasley, L., Thaler, S., Nicks, M., Price, B., Skorecki, K., and Nemenoff, R. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J. Biol. Chem., 272: 14501-14504, 1997. (Pubitemid 27251707)
72. Perillo, B., Tedesco, I., Laezza, C., Santillo, M., Romano, A., Aloj, S., and Bifulco, M. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in FRTL-5 cells. II> Down-regulation by v-K-ras oncogene. J. Biol. Chem., 270: 15237-15241, 1995.
73. Allgayer, H., Wang, H., Shirasawa, S., Sasazuki, T., and Boyd, D. Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogendependent proteolysis Br. J. Cancer, 80: 1884-1891, 1999. (Pubitemid 29391270)